Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum — starting with familial risk.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
Exact Sciences expects the test to be available in 2025, pending approval.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
The company’s commitment to community involvement keeps paying off when employees get back from giving back.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
Learning you may have or be at risk for cancer is hard. But getting ahead of it is becoming easier. Exact Sciences has a vision to help you discover and eradicate cancer early through one-of-a-kind tests that screen for cancer or help identify targeted treatments for your specific cancer.
Exact Sciences has developed a range of tests that can catch cancer before you know it or give you important information about the genes responsible for your diagnosed cancer. With this information in hand, you and your doctor can confidently choose a treatment path that may be most effective and personalized for you.
Right now, these tests focus on colorectal and breast cancers. But our scientific teams are also busy researching more cancers and developing multi-cancer testing to help many more people in the future. We're pleased to share some of our current clinical studies that will allow us to bring great new tests to patients.
At Exact Sciences, we conduct a range of clinical studies to rigorously assess the safety and performance of our tests in order to detect cancer earlier and guide optimal treatment.
We're pleased to highlight below some of our current clinical study efforts.
COLORECTAL CANCERSCREENING
DIAGNOSED COLORECTAL CANCER
LIVER CANCER SCREENING
MULTI-CANCERSCREENING
Exact Sciences, Mayo Clinic, University of Utah, American Cancer Society, and Fight Colorectal Cancer (Fight CRC) are working together on a clinical study to evaluate what impact an educational video about colorectal cancer screening has on patients completing their colorectal cancer screenings. Adults ages 45 to 70 who are scheduled for a primary care appointment, at average risk for colorectal cancer (CRC), and are due for CRC screening may be eligible to enroll. In addition to viewing the video, participants will be asked to complete several surveys over a 6-year study period.
For more information, refer to the link below.
Exact Sciences is conducting an international, observational study called CORRECT-I, enrolling Stage II and Stage III colorectal cancer patients. The aim of this study is to collect multiple blood samples over 5 years to evaluate if an investigational blood test is able to predict colorectal cancer recurrence by detecting minimal residual disease (MRD). Research sites are enrolling participants in Israel, Japan, Italy, Spain, and the United Kingdom.
Exact Sciences, National Surgical Adjuvant Breast and Bowel Project (NSABP) and Fight Colorectal Cancer (Fight CRC) are working together on an observational study called CORRECT-II, enrolling Stage II and Stage III colorectal cancer patients. The aim of this study is to collect multiple blood samples over 5 years to evaluate if an investigational blood test is able to predict colorectal cancer recurrence by detecting minimal residual disease (MRD).
For more information, refer to the clinicaltrials.gov link below. To find a participating site near you, please contact the NSABP Department of Site and Study Management at 1-800-270-3165 or by e-mail at industry.trials@nsabp.org.
Exact Sciences is currently conducting a clinical study called ALTUS, which is enrolling patients who are at increased risk for a type of liver cancer called hepatocellular carcinoma (HCC). In the study, participants will have radiology exams to check if HCC is developing and also provide blood samples for the Oncoguard® Liver blood test. The goal of the ALTUS study is to determine how well the Oncoguard Liver blood test can detect HCC in this patient population.
Exact Sciences is conducting the Falcon Registry study, a multi-site study to collect real-world evidence from up to 25,000 patients being tested with the Exact Sciences MCED test—a multi-cancer early detection (MCED) test. The Falcon Registry study aims to collect data about the course of care and outcomes for patients who are tested with the Exact Sciences MCED test under development, as well as any impact the testing may have on patient anxiety. The study will also gather data from a set of up to 50,000 patients who have received only single-cancer standard-of-care screening and will compare these data to those who were tested with the Exact Sciences MCED test. Those who enroll in the study will be offered the Exact Sciences MCED test once a year for up to three years and data will be collected for up to 5 years.
Detecting Cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A) Study
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.
Are you interested in participating in a Clinical Study? Here’s what you can do and what you can expect:
Reach out to your doctor to ask about a clinical study that seems related to your condition. Alternatively, your provider may suggest you participate in a specific clinical study that could help treat your condition. Study staff will ask you a few questions to see if you meet the requirements to join the study.
If you meet the eligibility requirements, a team of medical professionals will thoroughly discuss the study with you, give you time to ask questions, and review the informed consent form. Once you feel comfortable and have all your questions answered, you’ll provide written permission to start your participation in the study.
Arrive at the clinic for your first visit! After that, you will continue to come in for visits according to the clinical study schedule.
The two main types that Exact Sciences conducts are interventional studies and observational studies. Interventional Clinical Studies In an interventional clinical study, participants receive a specific intervention, which could be:
The intervention is then compared to the current standard of care for that condition.
This type of clinical study is often designed to determine whether the new intervention is more effective or no different than the standard of care.
Observational Studies In observational studies, clinical researchers observe and collect information about the participants to measure health outcomes.
Participants are not assigned to a specific intervention or compared to a different group of patients. Instead, researchers identify and enroll people who have already received a treatment or test in the past for a specific condition and analyze those results.
During the study, participants may be asked to answer questions, and report side effects or other challenges. They may also be asked to contribute biological samples, such as blood, saliva, or tissue that the researcher can test and use for their observations.
During the informed consent process, a study staff member will:
✔ Review the study information and what to expect as a study participant.
✔ Provide a form to be read and signed by the individual or their legal caregiver or guardian for permission to participate in the study.
✔ Share written materials and verbal instructions, and answer questions about the study.
Diversity is important to a study because biological, social, and economic factors can affect how people respond to a drug, test, or other intervention. To make sure that a scientific finding applies to everyone, studies should represent the broad community. This includes a wide range of ages, genders, races, ethnicities, insurance statuses, and other considerations. At Exact Sciences, we are dedicated to increasing diversity in our clinical studies by:
✔ Addressing barriers to equity in healthcare
✔ Educating research providers and the community about the importance of diversity in clinical research
✔ Including patient feedback into study design and planning.
An Institutional Review Board (IRB) is a group of clinicians, scientists, patient advocates, and community members. They are tasked with reviewing and approving clinical study protocols (plans), informed consent (written permissions to participate in a study) requirements and other study related materials. Studies involving human participants must be reviewed by an IRB before they can begin and are monitored throughout the study period. The IRB process safeguards the rights and welfare of clinical study participants. The IRB ensures that studies are well designed, ethical, legal and safe.
Anyone can participate in a clinical study if they meet the qualifications for that study. Some common factors that may be considered for study enrollment include:
✔ requiring participants to have a certain health conditions
✔ age at the time of enrollment
✔ whether a participant has previously been treated for the condition being studied.
Yes. Participating in a clinical study is voluntary and you can end your participation at any time and for any reason.
ClinicalTrials.gov: A database of publicly and privately funded clinical studies conducted around the world.
https://www.fda.gov/patients/clinical-trials-what-patients-need-know